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SUMMARY
OBJECTIVE: Diabetes is one of the leading causes of cardiovascular mortality. Over the last years, mortality has decreased significantly, 
more in individuals with diabetes than in healthy ones. That is mostly due to the control of other cardiovascular risk factors. The ob-
jective of our study was to analyze the dyslipidemia control in two diabetes cohorts.
METHODS: Patients from two distinct cohorts were studied, 173 patients from the BHS (Brasília Heart Study) and 222 patients from the 
BDS (Brazilian Diabetes Study). The data on dyslipidemia control were studied in both different populations. All patients had diabetes.
RESULTS: There are significant differences concerning comorbidities between the LDL-C and BDS groups. The average glycated hemo-
globin is of 8.2 in the LDL-C > 100 group in comparison with 7.7 and 7.5 in the 70-100 and < 70 groups, respectively (p = 0.024). There is a 
higher percentage of hypertensive patients with LDL between 70-100 (63.9%), when comparing the < 70 and > 100 groups (54.3% and 
54.9%, respectively; p = 0.005). Diastolic pressure is higher in the group with LDL > 100, with an average of 87 mmHg, in comparison 
with 82.6 mmHg and 81.9 mmHg in the 70-100 and < 70 groups, respectively (p = 0.019). The group with LDL > 100 has the greatest 
percentage of smokers (8.7%) in comparison with the groups with LDL between 70-100 and < 70 (5.6% and 4.3%, respectively; p = 
0.015). There is also a difference in the previous incidence of coronaropathy. In the group with LDL < 70, 28.3% of patients had already 
experienced a previous infarction, compared with 11.1% and 10.6% in the 70-100 and > 100 groups, respectively (p < 0.001).
CONCLUSIONS: The data in our study have shown that the dyslipidemia control in diabetic patients is inadequate and there is a tenden-
cy of direct association between lack of blood glucose control and lack of dyslipidemia control, in addition to the association with other 
cardiovascular risk factors, such as diastolic hypertension and smoking. This worsened control might be related to the plateau in the 
descending curve of mortality, and investments in this regard can improve the cardiovascular health in diabetic patients.
KEYWORDS: Dyslipidemias. Diabetes mellitus. Risk factors. Targets.
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INTRODUCTION
Diabetes is a huge cause of morbidity, mortality 
and economic impact. It affects 415 million individ-
uals worldwide¹, with an increase in prevalence over 
the past years, going from 4.7% in 1980 to 8.5% in 
2014, most significantly in countries with low and 
medium income². In Brasil, the estimated prevalence 
is of 8.1%. It is the direct cause of 6% of all deaths 
in the country, in addition to contributing to 31% of 
deaths attributed to cardiovascular disease³.
Over the last 30 years, cardiovascular mortality 
was substantially reduced, more so in diabetic indi-
viduals than in healthy ones, reaching a plateau af-
ter 2008-2010.4,5 In large part, this more favorable 
evolution of the cardiovascular prognosis in diabetic 
patients was due to an improved response to acute 
cardiovascular care in this population and also the 
improvement in the treatment of comorbidities such 
as hypertension and dyslipidemia.
The response to the lipid-lowering treatment has 
been widely demonstrated, and each reduction of 40 
mg/dL (1 mmol/L) in LDL cholesterol translates into 
20% less incidence of more serious cardiovascular 
events and 16% less cardiovascular mortality.6 Inter-
estingly, in a subanalysis of the Improve-IT study, 
only diabetic patients benefited from the addition of 
ezetimibe on top of the maximum dose of statin.7
Despite the relevancy of the subject, adherence to 
the lipid-lowering treatment is probably the most sig-
nificant barrier and must represent part of the expla-
nation for the plateau in the curve of mortality trend 
over the last decade. However, data on the control of 
LDL cholesterol in Brasil are very scarce and incon-
sistent. The most relevant data available on the sub-
ject comes from the Elsa study (Longitudinal Study 
of Adult Health) and suggests that the adequate con-
TABLE 1: CHARACTERISTICS OF PATIENTS ENROLLED 
IN THE BRAZILIAN DIABETES STUDY
LDL-C, mg/dL
>100 70-100 <70 p
N (222) 104 (47%) 72 (32%) 46 (21%)
Demographics
Age, years 58.6±6.9 59.8±7.1 61.1±6.5 0.106
Schooling, years 10.8±4.1 10.61±4.7 9.96±4.5 0.538
Men, % 53.8 55.6 73.9 0.058
Medical history
Previous AMI, % 10.6 11.1 28.3 <0.001
Smokers, % / For-
mer smokers, %
8.7/31.7 5.6/30.6 4.3/28.3 0.015/ 
0.011
Hypertension, % 54.8 63.9 54.3 0.005
Hemodynamics
SBP, mmHg 149.47±22.0 143.75±20.4 145.71±20.6 0.177
SBP, mmHg 87.09±13.2 82.65±10.2 81.9±12.8 0.019
HR, bpm 78.13±12.5 75.01±11.53 74.33±11.0 0.114




172.6±69.6 163.8±58.4 159.1±54.8 0.439
HbA1c, % 8.2±2.0 7.7±1.4 7.5±1.3 0.024
Creatinine, mg/dL 0.89±0.22 0.88±0.18 0.94±0.20 0.316
HDL-C, mg/dL 42.5±12.4 44.2±13.4 43.0±14.3 0.681
LDL-C, mg/dL 135.4±32.1 88.1±8.0 58.0±10.5 <0.001
TG, mg/dL 234.5±138 158.7±92.6 153.7±156.5 <0.001
PCRus, mg/L 0.42±0.54 0.32±0.32 0.35±0.41 0.343
Treatment
Simvastatin, % 21 38 53 <0.001
SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; HbA1C: 
glycated hemoglobin; TG: triglycerides; CRP: ultrasensitive C-reactive protein.
TABLE 2: CHARACTERISTICS OF PATIENTS ENROLLED 
IN THE BRASÍLIA HEART STUDY
LDL-C, mg/dL
>100 70-100 <70 p
N (173) 113 (65%) 37(21%) 23 (13%) 
Demographics
Age, years 62.24±9.9 64.51±11.4 61.48±10.8 0.441
Schooling, years 7.3±4 7.2±5 7.6±5 0.944
Men, % 67.3 64.9 73.9 0.759
BMI, kg/m2 27.7±4 28.2±6 27.4±4 0.726
Medical history
Previous AMI % 12.4% 27.0% 21.7% 0.093
Smoker, % 69.9 67.6 69.6 0.964
Hypertension, % 29.2 18.9 30.4 0.442
Hemodynamics
SBP, mmHg 137±30 141±36 128±26 0.317
SBP, mmHg 87±19 86±20 82±19 0.579




206±87 200±84 191±98 0.741
HbA1c, % 8.1±2.3 8.1±2.0 8.1±1.9 0.983
Cr, mg/dL 1.16±0.35 1.18±0.52 1.15±0.71 0.966
HDL-C, mg/dL 39.0±9.8 37.0±10.4 27.1±10.0 <0.001
LDL-C, mg/dL 140.7±34.9 88.3±8.0 56.7±13.8 <0.001
TG, mg/dL 166.7±73.2 142.2±90.8 175.4±130.1 0.247
PCRus, mg/L 1.39±2.25 2.45±4.04 2.26±4.20 0.120
Treatment
Simvastatin, % 28.8 27.8 30.4 0.976
SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; HbA1C: 
glycated hemoglobin; TG: triglycerides; CRP: ultrasensitive C-reactive protein.
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trol of dyslipidemia in the general population is low-
er than 10%.8 However, it is well known that the Elsa 
population had an educational background different 
from that of most of the Brazilian population (52.6% 
with complete higher education). In the diabetic pop-
ulation, data are even more scarce, which has limited 
the development of public policies that address this 
group of patients.
The purpose of this study is to analyze data con-
cerning the dyslipidemia control in diabetic patients 
using the population from two Brazilian cohorts.
METHOD
The population of this study is composed of indi-
viduals from two distinct cohorts, with 173 patients 
from the BHS (Brasília Heart Study) and 222 patients 
from the BDS (Brazilian Diabetes Study). There were 
no patients who participated in both cohorts.
Brasília Heart Study
The patients included in the BHS were consecu-
tively enrolled provided they presented a diagnosis 
of infarction with ST-segment elevation admitted 
within 24 hours of the onset of pain at the Basic Hos-
pital of the Federal District, the largest public hos-
pital of the Federal Capital. A total of 173 patients 
admitted between 2006 and 2017 were included in 
the analysis. The inclusion criteria were: (i) less than 
24 hours from the onset of the AMI symptoms; (ii) 
ST-segment elevation of at least 1 mm (frontal plane) 
or 2 mm (horizontal plane) in two contiguous leads; 
(iii) evidence of myocardial necrosis due to the rise 
in CK-MB and troponin; (iv) glycated hemoglobin 
> 6.5% or a previous diagnosis of diabetes with use 
of anti-diabetic medication; (v) absence of cognitive 
incompetence that prevents the verbal response to 
medical questionnaires or the return to medical con-
sultations. During the evaluation, will be carried out: 
(i) anthropometry; (ii)analysis of dietary composition 
through a recall questionnaire; (iii) general medical 
records; (iv) blood samples for biochemical analysis 
and separation of plasma and DNA for freezing at - 
80°C. In the plasma biochemical analysis of the first 
evaluation will be measured: glycated Hemoglobin, 
insulin, C-peptide, blood glucose, total cholesterol, 
triglycerides, HDL cholesterol, high-sensitivity C-re-
active protein, urea, and creatinine. This study was ap-
proved by the ethics committee of the Federal District 
Secretariat of Health, and all patients enrolled signed 
an informed consent form authorizing the study. 
Brazilian Diabetes Study
The BDS is a cohort formed between 2016 and 
2018 with diabetic patients admitted after a cam-
paign in print media, radio, and television. Thus, 
the population studied is composed of voluntary di-
abetic individuals assessed in the Clinical Research 
Center (CPC) of the State University of Campinas 
(Unicamp). The inclusion criteria were: (i) patients 
with type 2 diabetes mellitus (DM2), (ii) between 40 
and 70 years old, (iii) absence of cognitive incompe-
tence that prevents verbal response to medical ques-
tionnaires and the informed consent form. The ex-
clusion criteria were: (i) patients diabetes mellitus 
phenotypes other than DM2; (ii) insulin-dependent 
individuals. In the first assessment, the study was 
explained in detail to the patients, and the informed 
consent form was presented. Then, the patients’ 
identification and contact information were collect-
ed, followed by the medical history and a complete 
physical examination; the arterial pressure mea-
sured while seating and standing, the abdominal 
circumference, height, and weight were recorded. 
Finally, the patient’s pharmacological characteriza-
tion was recorded, and a diabetic polyneuropathy 
assessment conducted, in addition to data concern-
ing the socioeconomic conditions and lifestyle. The 
research ethics committee of Unicamp approved 
the study, and all the patients signed the informed 
consent form in order to be enrolled in the study. 
Statistical analysis
The quantitative data were presented as aver-
age +/- standard deviation. Comparison between the 
groups was carried out using the Student t-test for 
parametric continuous variables, the Mann-Whitey 
test for non-parametric continuous variables, and 
the χ2 test for continuous variables. The statistical 
analysis was performed using the SPSS version 20.0 
(SPSS Inc., Chicago, Illinois, USA).
RESULTS
In the Brasília Heart Study, there were no statis-
tically significant differences in demographic factors 
between the groups with the best and worst dyslipid-
emia control (age, years of formal education, sex, and 
body mass index). The average of formal education in 
the cohort was 7.32 of studying. As for the dyslipid-
PREVALENCE, TREATMENT, AND CONTROL OF DYSLIPIDEMIA IN DIABETIC PARTICIPANTS OF TWO BRAZILIAN COHORTS: A PLACE FAR FROM HEAVEN
REV ASSOC MED BRAS 2019; 65(1):3-8 6
emia control, 21% of the patients reached LDL-C < 70 
(good), 32% between 70-100 (intermediate) and 47% > 
100 mg/dL (inadequate).
As for the prevalence of comorbidities between 
the LDL-C groups, there was also no statistically sig-
nificant difference between the prevalence of chron-
ic liver disease and hypertension, and the average 
glycated hemoglobin in the groups with LDL-C < 70, 
LDL-C = 70-100, and LDL-C > 100 mg/dL was of 8.1 (p 
= 0.966), which suggests that the adequate control 
of LDL-Cis independent from the adequate control of 
blood glucose targets.
In the Brazilian Diabetes Study (BDS), there were 
also no statistically significant differences between 
the LDL-C groups in comparison with demographic 
factors. The is a non-significant tendency of a greater 
number of men in the LDL-C < 70 (73.9%) group in 
comparison with the 70-100 and > 100 mg/dL groups 
(55.6% and 53.8%, respectively; p = 0.058). Although 
the average formal schooling in this cohort (10.57 
years of studying) is higher than in the BHS cohort, 
the dyslipidemia control was worse, with only 13% of 
patients reaching DL-C < 70 (good), 21% between 70-
100 (intermediate), and 65% > 100 (inadequate).
However, there are noteworthy statistically signif-
icant differences concerning comorbidities between 
the LDL-C groups. Concerning diabetes, there was a 
higher lack of blood glucose control in the group with 
a greater lack of dyslipidemia control. The average gly-
cated hemoglobin is of 8.2 in the LDL-C > 100 group 
in comparison with 7.7 and 7.5 in the 70-100 and < 70 
groups, respectively (p = 0.024). There is a higher per-
centage of hypertensive patients with LDL between 
70-100 (63.9%), when comparing the < 70 and > 100 
groups (54.3% and 54.9%, respectively; p = 0.005). Dia-
stolic pressure is higher in the group with LDL > 100, 
with an average of 87 mmHg, in comparison with 82.6 
mmHg and 81.9 mmHg in the 70-100 and < 70 groups, 
respectively (p = 0.019). The group with LDL > 100 has 
the greatest percentage of smokers (8.7%) in compari-
son with the groups with LDL between 70-100 and < 70 
(5.6% and 4.3%, respectively; p = 0.015). There is also 
a difference in the previous incidence of coronaropa-
thy. In the group with LDL < 70, 28.3% of patients had 
already experienced a previous infarction, compared 
with 11.1% and 10.6% in the 70-100 and > 100 groups, 
respectively (p < 0.001). Thus, it is reasonable to con-
clude that chasing more aggressive targets of LDL-C is 
more frequent for diabetic patients in secondary pre-
vention than to those on primary prevention.
DISCUSSION
Our work was one of the few in Brasil that pro-
posed to evaluate the dyslipidemia control in diabetic 
populations. The results show that in both popula-
tions the control is beneath the desired (prevalence 
of adequate control of 32% in BHS and 13% in BDS) 
and that the prevalence of dyslipidemia is high.
A similar study was Elsa, composed of public 
servants from six institutions of higher education 
and research in Brasil. The prevalence of diabetes, 
however, was of only 19.1%, and the control with 
LDL < 70 was reached in 2.5% patients.8 Another 
critical difference in this study is the level of formal 
education, with a greater prevalence of individuals 
with completed higher education. This suggests a 
higher socioeconomic level of the participants, with 
a likely prevalence of patients who already had 
medical follow-up by private or insurance medical 
professionals.
The difference in the prevalence of a previous cor-
onaropathy found in the BDS can be explained by the 
secondary prevention since patients with a previous 
ischemic event usually have a more intense and rig-
orous control of dyslipidemia.9 
Other findings of the BDS are compatible with 
previous results in the literature: the patients with 
worst dyslipidemia control have a higher incidence 
of smoking10 in this same population, present a 
higher diastolic pressure11-13 and, lastly, which is 
the purpose of the research, a worse blood glucose 
control was found in patients with higher levels of 
LDL14,15. 
In the Elsa study, it was found that the preva-
lence, awareness, and control of dyslipidemia were 
higher in men, black, and with less formal educa-
tion.8 In the populations studied in our work, how-
ever, we found a higher dyslipidemia control in pa-
tients with lower levels of formal education. Again, 
the greater prevalence of patients with a higher 
socioeconomic level among the group with higher 
formal education might suggest a follow-up by pri-
vate or insurance doctors. In this sense, the guide-
lines by the Brazilian Society of Endocrinology and 
Metabolism proposes to identify the cardiovascular 
risk for each patient, considering that each diabet-
ic individual has a unique risk and, thus, rejecting 
the theory that everyone has a high cardiovascular 
risk. In contrast, the guidelines by the Brazilian So-
ciety of Cardiology (SBC) suggests strict targets for 
LDL-C, at < 70 for everyone with high cardiovascu-
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associação direta entre descontrole glicêmico e descontrole de dislipidemia, além de associação com outros fatores de risco cardiovas-
cular, como hipertensão diastólica e tabagismo. Esse pior controle pode estar relacionado ao platô no descenso da curva de mortali-
dade, e o investimento nesse quesito pode melhorar a saúde cardiovascular dos diabéticos.
PALAVRAS-CHAVE: Dislipidemias. Diabetes mellitus. Fatores de risco. Metas.
lar risk - a group that includes diabetic individuals. 
This recommendation is based on studies that show 
a decrease in cardiovascular events in diabetic pa-
tients undergoing a strict control of lipids16-18.
As limitations, we can mention the small sample 
of patients in each of the cohorts used in our work 
in comparison with the Elsa study, for example. Be-
sides, there were no statistically significant associ-
ations between the groups of patients of the BHS. 
Lastly, the inclusion criteria in the cohorts usually 
selects patients with specific profiles; thus, the data 
found are not representative of the general diabetic 
population in Brasil.
In conclusion, there are few data on the dyslipid-
emia control in the Brazilian population, especially 
in people with diabetes. The data in our study shows 
that the control is inadequate and that there is a 
tendency of direct association between the lack of 
blood glucose control and the lack of dyslipidemia 
control, in addition to the association with other 
risk factors, such as diastolic hypertension and 
smoking. The limited control of dyslipidemia might 
be related to the plateau in the curve of mortality 
trend for diabetic individuals over the last decade. 
Inventing in the control of comorbidities, such as 
dyslipidemia, can potentially prolong survival and 
translate into improved cardiovascular health for 
diabetic individuals.
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